The European Patent Office boards of appeal are unlikely to be able to reduce the case backlog anytime soon, but attorneys should be wary of possible changes in board practice, former board head Alec Clelland told the Chartered Institute of Patent Attorneys (CIPA) Life Sciences conference.
If you have already subscribed please login.
If you have any technical issues please email tech support.
CIPA Life Sciences, EPO boards of appeal, European Patent Office, Alec Clelland
